These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
393 related articles for article (PubMed ID: 32384184)
1. Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response. Navani V; Graves MC; Bowden NA; Van Der Westhuizen A Br J Clin Pharmacol; 2020 Sep; 86(9):1736-1752. PubMed ID: 32384184 [TBL] [Abstract][Full Text] [Related]
2. Immune-Checkpoint Blockade Therapy in Lymphoma. Kuzume A; Chi S; Yamauchi N; Minami Y Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751706 [TBL] [Abstract][Full Text] [Related]
3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
4. Recent advances in the clinical development of immune checkpoint blockade therapy. Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647 [TBL] [Abstract][Full Text] [Related]
5. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Xia L; Liu Y; Wang Y Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829 [TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Hargadon KM; Johnson CE; Williams CJ Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692 [TBL] [Abstract][Full Text] [Related]
7. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041 [TBL] [Abstract][Full Text] [Related]
8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Blockade in Breast Cancer Therapy. Bu X; Yao Y; Li X Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694 [TBL] [Abstract][Full Text] [Related]
10. The application of nanotechnology in immune checkpoint blockade for cancer treatment. Deng H; Zhang Z J Control Release; 2018 Nov; 290():28-45. PubMed ID: 30287266 [TBL] [Abstract][Full Text] [Related]
11. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. Signorelli D; Giannatempo P; Grazia G; Aiello MM; Bertolini F; Mirabile A; Buti S; Vasile E; Scotti V; Pisapia P; Cona MS; Rolfo C; Malapelle U; Biomed Res Int; 2019; 2019():9056417. PubMed ID: 31179334 [TBL] [Abstract][Full Text] [Related]
16. Cytokines as potential combination agents with PD-1/PD-L1 blockade for cancer treatment. Rahimi Kalateh Shah Mohammad G; Ghahremanloo A; Soltani A; Fathi E; Hashemy SI J Cell Physiol; 2020 Jul; 235(7-8):5449-5460. PubMed ID: 31970790 [TBL] [Abstract][Full Text] [Related]
17. Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know. Braschi-Amirfarzan M; Tirumani SH; Hodi FS; Nishino M Korean J Radiol; 2017; 18(1):42-53. PubMed ID: 28096717 [TBL] [Abstract][Full Text] [Related]
18. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. Li K; Tian H J Drug Target; 2019 Mar; 27(3):244-256. PubMed ID: 29448849 [TBL] [Abstract][Full Text] [Related]
19. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics. Han X; Li H; Zhou D; Chen Z; Gu Z Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988 [TBL] [Abstract][Full Text] [Related]
20. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors? Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]